| 1 |
35015683 | Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. | 2022 Mar 1 |
2 |
| 2 |
35015686 | Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies. | 2022 Mar 1 |
2 |
| 3 |
35043731 | Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia. | 2022 Jan 19 |
1 |
| 4 |
35121370 | Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. | 2022 Mar |
1 |
| 5 |
35468945 | Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. | 2022 Jun |
1 |
| 6 |
35500285 | CD22low/Bcl-2high expression identifies poor response to inotuzumab in relapsed/refractory acute lymphoblastic leukemia. | 2022 May 2 |
1 |
| 7 |
35618655 | Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment. | 2022 May 26 |
1 |
| 8 |
35635686 | A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). | 2022 May 30 |
3 |
| 9 |
32812370 | Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. | 2021 Jan |
1 |
| 10 |
33067614 | A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). | 2021 Mar 25 |
1 |
| 11 |
33602684 | Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. | 2021 May 15 |
2 |
| 12 |
34172894 | Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. | 2021 Nov |
1 |
| 13 |
34331563 | Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin. | 2021 Nov |
3 |
| 14 |
34441852 | Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia. | 2021 Aug 13 |
1 |
| 15 |
32291234 | Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. | 2020 Aug |
1 |
| 16 |
32424837 | Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia. | 2020 Jul |
1 |
| 17 |
32648276 | Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia. | 2020 Oct |
1 |
| 18 |
32682148 | B cell modulation strategies in the improvement of transplantation outcomes. | 2020 Sep |
1 |
| 19 |
32860590 | Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. | 2020 Oct |
1 |
| 20 |
32908056 | [Antibody therapy for acute lymphoblastic leukemia]. | 2020 |
1 |
| 21 |
33279181 | Antibody based therapy in relapsed acute lymphoblastic leukemia. | 2020 Dec |
1 |
| 22 |
33292550 | Recent updates for antibody therapy for acute lymphoblastic leukemia. | 2020 Nov 27 |
1 |
| 23 |
30120894 | Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin). | 2019 Feb |
1 |
| 24 |
30807395 | Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance. | 2019 Nov |
3 |
| 25 |
30834235 | Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53. | 2019 |
2 |
| 26 |
31011424 | Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. | 2019 |
1 |
| 27 |
31039409 | Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. | 2019 Sep |
1 |
| 28 |
28859185 | Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. | 2018 Feb 1 |
1 |
| 29 |
29352703 | Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. | 2018 Feb |
1 |
| 30 |
29508899 | Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. | 2018 May 15 |
1 |
| 31 |
29572070 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). | 2018 Jun |
1 |
| 32 |
29713210 | Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. | 2018 |
1 |
| 33 |
30087554 | Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. | 2018 |
2 |
| 34 |
30090971 | Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia. | 2018 Aug |
2 |
| 35 |
30362019 | Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies. | 2018 Dec |
1 |
| 36 |
30372691 | Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. | 2018 |
1 |
| 37 |
30442119 | Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. | 2018 Nov 15 |
1 |
| 38 |
30504286 | Antibody-based therapies in patients with acute lymphoblastic leukemia. | 2018 Nov 30 |
1 |
| 39 |
31186988 | Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. | 2018 Sep-Oct |
1 |
| 40 |
33815734 | Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. | 2018 |
1 |
| 41 |
27820973 | Emerging biological therapies to treat acute lymphoblastic leukemia. | 2017 Mar |
1 |
| 42 |
28152223 | Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. | 2017 May |
1 |
| 43 |
28776425 | Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. | 2017 Oct |
1 |
| 44 |
28819740 | Inotuzumab Ozogamicin: First Global Approval. | 2017 Sep |
4 |
| 45 |
29296758 | Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. | 2017 Jun 27 |
2 |
| 46 |
29517084 | Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia. | 2017 Dec |
2 |
| 47 |
26654587 | Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia. | 2016 |
1 |
| 48 |
26780449 | Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. | 2016 Feb |
1 |
| 49 |
26783163 | Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. | 2016 |
1 |
| 50 |
27154915 | Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. | 2016 Oct 1 |
2 |